Analysts Estimate Thermo Fisher Scientific (TMO) to Report a Decline in Earnings: What to Look Out for

Thermo Fisher Scientific (TMO) is anticipated to report a year-over-year earnings decline to $5.22 per share for the quarter ended June 2025, despite projected 1% revenue growth to $10.65 billion, with results due July 23. While the company has historically beaten EPS estimates, its current Zacks Earnings ESP of -0.35% and Zacks Rank of #4 suggest analysts have recently turned more bearish, making an earnings beat less likely this quarter. This combination indicates TMO is not a strong candidate for a positive earnings surprise, which could influence near-term stock performance.

Analysis

Thermo Fisher Scientific (TMO) is approaching its Q2 2025 earnings report with a challenging outlook, as consensus estimates project a 2.8% year-over-year decline in EPS to $5.22 despite a forecasted 1% increase in revenue to $10.65 billion. This divergence between top-line growth and bottom-line contraction suggests potential margin pressure. While the company has a strong track record of beating EPS estimates for the last four consecutive quarters, current quantitative indicators are bearish. The Zacks Earnings ESP is -0.35%, indicating that the most recent analyst revisions are lower than the consensus, and the stock carries a Zacks Rank of #4 (Sell). This combination makes it statistically difficult to predict an earnings beat. Although the consensus EPS estimate has remained stable over the past 30 days, the negative ESP and rank suggest that near-term sentiment among analysts has soured, creating a cautious setup for the stock heading into its July 23 report.

Key Decisions for Investors

• Investors should exercise caution ahead of the earnings release, as the negative Earnings ESP of -0.35% and a Zacks Rank of #4 (Sell) point to a low probability of a positive surprise, contrary to the company's recent history.
• The primary focus for the earnings call should be on management's commentary regarding the disparity between the 1% revenue growth and the 2.8% earnings decline, which signals potential margin erosion.
• Be prepared for the stock's performance to be heavily influenced by forward guidance, as a miss, or even a beat accompanied by a weak outlook, could lead to negative price action.